Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists
C Metcalfe, FJ de Sauvage - Cancer research, 2011 - AACR
Cancer research, 2011•AACR
Acquired resistance to targeted therapies threatens the value of these otherwise very
promising agents. The recent description of resistance to the Hedgehog pathway inhibitor
vismodegib (GDC-0449) in a medulloblastoma patient who had a dramatic initial response
has spurred efforts to understand potential mechanisms of drug resistance. Elucidating
these mechanisms will play a significant role in informing strategies to overcome this
meaningful limitation. Cancer Res; 71 (15); 5057–61.© 2011 AACR.
promising agents. The recent description of resistance to the Hedgehog pathway inhibitor
vismodegib (GDC-0449) in a medulloblastoma patient who had a dramatic initial response
has spurred efforts to understand potential mechanisms of drug resistance. Elucidating
these mechanisms will play a significant role in informing strategies to overcome this
meaningful limitation. Cancer Res; 71 (15); 5057–61.© 2011 AACR.
Abstract
Acquired resistance to targeted therapies threatens the value of these otherwise very promising agents. The recent description of resistance to the Hedgehog pathway inhibitor vismodegib (GDC-0449) in a medulloblastoma patient who had a dramatic initial response has spurred efforts to understand potential mechanisms of drug resistance. Elucidating these mechanisms will play a significant role in informing strategies to overcome this meaningful limitation. Cancer Res; 71(15); 5057–61. ©2011 AACR.
AACR